

## SUPPORTING INFORMATION

for

### **LT2 *Cryptosporidium* Data...What do they tell us about *Cryptosporidium* in Surface Water in the USA?**


by: Jerry E. Ongerth<sup>1</sup>

#### **SI Figure List**


S1 Fig. 2- USA LT2 data analysis locations	S10 Fig. 6f- LogProb LT2 10 MO AR OK & LA
S2 Fig.3- LogProb LT2 5MWst & 3SLC	S11 Fig. 7a- LogProb LT2 9 Indiana
S3 Fig. 4- LogProb LT2 8 MS R	S12 Fig. 7b- LogProb LT2 11 TN VA FL & KY
S4 Fig. 5- LogProb LT2 7 MO R	S13 Fig. 7c- LogProb LT2 14 DE MD NJ & PA
S5 Fig. 6a- LogProb LT2 6 CO & 3SLC	S14 Fig. 7d- LP LT2 14 OH PA NY MA & CT
S6 Fig. 6b- LogProb LT2 7 KS	S15 Fig. 7e- LogProb LT2 11 CA & NV
S7 Fig. 6c- LogProb LT2 10 IL IA MN & ND	S16 Fig. 8- Log Prob LT2 50 Rep Sites
S8 Fig. 6d- LogProb LT2 9 NC & SC	S17 Fig. 8b- LogProb LT2 50 w Loc & MSs
S9 Fig. 6e- LogProb LT2 9 San Marcos TX	

\*Corresponding Author. Mailing Address: Prof. J. E. Ongerth, CME Bldg 4 EEC, University of Wollongong, Wollongong NSW 2522, Australia. Tel: ++61 0408 548 427. Fax: ++61 2 4221 3238. Email: [jongerth@uow.edu.au](mailto:jongerth@uow.edu.au).


22/03/2013 8:46 PM




**S1 Figure 2.** USA map with locations and site numbers of 160 LT2 sampling sites reporting highest numbers of non zero *Cryptosporidium* oocyst FS findings.




**S2 Figure 3.** Log probability distributions LT2 *Cryptosporidium* occurrence data for eight sampling sites in the central USA.



**S3 Figure 4.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at seven sampling sites on the Mississippi River.




**S4 Figure 5.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at six sampling sites on the Missouri River.




**S5 Figure 6a.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at six sampling sites in Colorado and Utah.






**S6 Figure 6b.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at seven sampling sites in Kansas.




**S7 Figure 6c.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at ten sampling sites in Illinois, Iowa, Minnesota, and North Dakota.







**S8 Figure 6d.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at nine sampling sites in North and South Carolina.




**S9 Figure 6e.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at nine sampling sites in Texas.



**S10 Figure 6f.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at ten sampling sites in Arkansas, Louisiana, and Missouri.




**S11 Figure 7a.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at nine sampling sites in Indiana.




**S12 Figure 7b.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at eleven sampling sites in Florida, Kentucky, Tennessee, and Virginia.






**S13 Figure 7c.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at fourteen sampling sites in Delaware, Maryland, New Jersey, and Pennsylvania.







**S14 Figure 7d.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at fourteen sampling sites in Connecticut, Ohio, Massachusetts, New York, and Pennsylvania.



**S15 Figure 7e.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at ten sampling sites in California and Nevada.



**S16 Figure 8.** Log probability LT2 *Cryptosporidium* oocyst distributions with site locations and reported MS recovery fractions at fifty sampling sites in every region of the USA.



**S17 Figure 8b.** Compilation of log-normal probability distributions of LT2 *Cryptosporidium* occurrence data the 50 r USA sampling sites with site in Figure 8 with site names and measured MS values listed.